AG
Goncalves Cabecinhas, Ana Rita
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Swiss community-based surveillance of respiratory virus co-occurrence in 2022–2024 | Microbiology spectrum |  | 2026 | 4 | 4 | ||
| Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data | Science translational medicine | | 2023 | 84 | 81 | ||
| Prevalence of immunoglobulin G (IgG) against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) andeEvaluation of a rapid MEDsan IgG test in children seeking medical care | Clinical Infectious Diseases | | 2021 | 305 | 381 | ||
| SARS-CoV-2 N501Y introductions and transmissions in Switzerland from beginning of october 2020 to february 2021-implementation of swiss-wide diagnostic screening and whole genome sequencing | Microorganisms | | 2021 | 243 | 349 | ||
| Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells | Frontiers in Immunology | | 2019 | 364 | 235 | ||
| Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient | Antiviral Therapy | | 2019 | 282 | 284 | ||
| Comparative analysis of viral shedding in pediatric and adult subjects with central nervous system-associated enterovirus infections from 2013 to 2015 in Switzerland | Journal of Clinical Virology | | 2017 | 593 | 263 | ||
| Hospital surveillance of influenza strains: a concordant image of viruses identified by the Swiss Sentinel system? | Influenza and other Respiratory Viruses | | 2017 | 1,476 | 544 | ||
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | | 2016 | 936 | 294 | ||
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases |  | 2015 | 708 | 0 |
